阿爾凱默斯 ALKS 深 滬
已收盤 06-18 16:00:00 美东时间
44.99
+0.480
+1.08%
華盛通- 最 高45.76
- 今 開45.25
- 成交量 775.14万股
- 最 低 43.98
- 昨 收 44.51
- 總市值 74.99亿
- 52周最高 45.76
- 市盈率 靜 31.42
- 換手率 4.65%
- 52周最低 25.165
- 委 比 -97.80%
- 總股本 1.67亿
- 歷史最高 79.041
- 量 比 4.59
- 振 幅 4.00%
- 歷史最低 10.311
- 每 手 1
- 風險率 4.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Stifel cut the price target for Intuit Inc (NASDAQ:INTU) from $375 to $275. Stifel analyst Brad Reback downgra...
06-18 22:31
Needham Maintains Buy on Alkermes, Raises Price Target to $54
Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target from $50 to $54.
06-18 17:50
直击大脑“觉醒开关”！阿尔凯默斯(ALKS.US)嗜睡症新药中期数据报捷 食欲素赛道点燃制药竞赛
阿尔凯默斯(ALKS.US)周三在巴尔的摩举行的睡眠医学年会上公布，其实验性药物alixorexton在2型嗜睡症（narcolepsy type 2）患者中显著改善了觉醒维持能力。
06-18 13:52
Alkermes releases mid-stage alixorexton data for narcolepsy
Alkermes reported positive phase 2 study results of alixorexton for narcolepsy type 2 after Wednesday's market close. The Vibrance-2 trial met its dual primary endpoints: improvement from baseline com...
06-18 05:07
Alkermes Drug Gets Orphan Status in US and Europe, Wins Rare Disease Designations for Alixorexton
Alkermes plc (NASDAQ:ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), was recently granted orphan drug designations ...
06-15 19:16
自上次财报发布以来，Alkermes（ALKS）股价上涨21.1%：涨势能否延续？
自阿尔克梅斯公司（Alkermes，ALKS）发布上一份财报约一个月，股价上涨约21.1%，优于标普500指数。 2026年第一季度，该公司每股亏损40美分，小...
06-15 15:15
Alkermes' alixorexton gains FDA orphan drug status for idiopathic hypersomnia
The US FDA has granted orphan drug designation to Alkermes' (ALKS) alixorexton for idiopathic hypersomnia. The oral orexin 2 receptor agonist is currently in phase 2. The condition is characterized by...
06-12 01:34
美股大行评级 | 潜在涨幅321.55%！Shattuck Labs获花旗升目标价至18美元，维持"买入"评级
今日重点评级关注：花旗：维持Shattuck Labs"买入"评级，目标价从7美元升至18美元；Benchmark：维持Gloo Holdings"买入"评级，目标价从14美元升至15美元
06-10 12:32
Alkermes Plans To Present New Data From Portfolio Of Sleep Medicine Research At SLEEP 2026, Including Posters Featuring LUMRYZ Extended-Release Oral Suspension, And Alixorexton
— 26 Abstracts Accepted Demonstrate Alkermes' Commitment to Advancing Understanding and Treatment of Narcolepsy and Idiopathic Hypersomnia —— Detailed Positive Results from Vibrance-2 Phase 2 Study of Alixorexton, an
06-04 19:08
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
